US 12,281,123 B2
Benzoxazinone compounds as KLK5/7 dual inhibitors
Andreas Betz, Palo Alto, CA (US); and Robert Zamboni, Palo Alto, CA (US)
Assigned to MOLECULAR SKIN THERAPEUTICS, INC., Palo Alto, CA (US)
Filed by MOLECULAR SKIN THERAPEUTICS, INC., Palo Alto, CA (US)
Filed on Apr. 3, 2023, as Appl. No. 18/295,009.
Application 18/295,009 is a continuation of application No. 17/037,910, filed on Sep. 30, 2020, granted, now 11,643,420.
Claims priority of provisional application 62/909,006, filed on Oct. 1, 2019.
Prior Publication US 2024/0067658 A1, Feb. 29, 2024
Int. Cl. C07D 498/04 (2006.01); A61K 9/00 (2006.01); A61P 17/00 (2006.01)
CPC C07D 498/04 (2013.01) [A61K 9/0014 (2013.01); A61P 17/00 (2018.01)] 6 Claims
 
1. A method of treating Netherton Syndrome in a subject in need thereof, comprising administering to said subject a pharmaceutical composition comprising:
a) an effective amount of a compound having formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable complex thereof; and
b) a pharmaceutically acceptable carrier,
wherein R is H or a member selected from the group consisting of —R1 and —C(O)R1a, wherein R1 is C1-12 alkyl, and R1a is H or C1-12 alkyl.